ArticleInternational journal of clinical and experimental pathology2017
Prognostic significance of stromal SMYD3 expression in colorectal cancer of TNM stage I-III.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 7 citations in OpenAlex.
- Genetic Alterations ofInternational journal of molecular sciences · 2024Article
- Playing on the Dark Side: SMYD3 Acts as a Cancer Genome Keeper in Gastrointestinal Malignancies.Cancers · 2021Review
- SMYD3: a regulator of epigenetic and signaling pathways in cancer.Clinical epigenetics · 2021Review
- SMYD3 promotes colon adenocarcinoma (COAD) progression by mediating cell proliferation and apoptosis.Experimental and therapeutic medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSET and MYND domain-containing protein 3 (SMYD3) is a histone methyltransferases and it promotes progression of many kinds of cancers including lung cancer, ovarian cancer and gastric cancer. In colorectal cancer (CRC), SMYD3 is proved to stimulate the proliferation of cancer cells, but the clinical significance of SMYD3 in CRC has not been elucidated.
methodsIn our study, we detected the expression of SMYD3 in CRC samples in TNM stage I-III with immunohistochemistry. The correlation between the expression of SMYD3 and the clinicopathological factors was analyzed with Chi-square test. The survival curve was displayed by Kaplan-Meier test and the statistical difference of subgroups was analyzed with log-rank test. Independent prognostic factors were identified by the Cox proportional hazards regression model.
resultsThe percentage of high SMYD3 expression and low expression accounts for 47.98% and 52.02% respectively. High expression of SMYD3 was significantly associated with advance T stage (P=0.006) and lower survival rates (P=0.010), and it could be identified as an independent prognostic factor indicating unfavorable prognosis of patients with CRC (P=0.032, HR=1.98, 95% CI=1.06-3.70).
conclusionsSMYD3 high-expression is a high risk for poorer prognosis of CRC in TNM stage I-III. Our findings suggested that detecting SMYD3 may help stratify patients by risk more preciously and help make the individual treatment strategy.
Indexed as
Identifiers
31966758PMC6965370W3018397906What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.